MetaCap

Nasus Pharma (NSRX) vs Rein Therapeutics (RNTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nasus Pharma (NSRX) has outperformed Rein Therapeutics (RNTX) over the past year, losing 68.4% versus a loss of 77.2%. Rein Therapeutics is the larger company by market cap ($29.1 million vs $26.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NSRX-68.41%RNTX-77.24%
+32%-25%-82%
Nov 21, 20251 yearNov 20, 2026
NSRX-71.73%RNTX-71.78%
+53%-13%-79%
Aug 11, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NSRX versus RNTX key metrics
MetricNSRXRNTX
Share price$2.29$0.3369
Market cap$26.82M$29.06M
1-day change-10.20%-8.38%
YTD return-74.97%-70.96%
1-year return-68.41%-77.24%
5-year return—-97.47%
EPS (TTM)$-1.20$-1.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.24B$0
Net income (latest FY)$-5.86M$-49.87M
Operating margin-0.40%—
Net margin-0.47%—
52-week high$9.50$2.10
52-week low$1.98$0.284
Distance from 52-week high-75.89%-83.96%
Analyst consensusbuynone
Avg. price target upside+758.95%+1680.94%
Average volume16.80K586.68K
Shares outstanding11.71M86.27M
Employees710
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Nasus Pharma

NSRX stock →

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Rein Therapeutics

RNTX stock →

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

NSRX vs RNTX FAQ

Which is bigger, Nasus Pharma or Rein Therapeutics?

Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $26.82M for Nasus Pharma (NSRX).

Which stock has performed better over the past year, NSRX or RNTX?

NSRX returned -68.41% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.

Are Nasus Pharma and Rein Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons